MT Group

02/18/2026

MT Group is thrilled to participate in the 25th Precision Medicine World Conference, taking place March 4–6, at the Santa Clara Convention Center in California.

We will be exhibiting at booth where speakers and exhibitors will gather to help advance precision medicine & AI.

Reach out to us today to book a meeting at the conference! https://mtgroupbio.com/contact-us/

01/22/2026

Clinical trials collect biospecimens, but rarely enough for all the translational work running alongside them. When protocols can't be amended quickly, one approach is running a parallel study—same patient population, additional samples, no protocol changes required.

Learn more at our website: https://mtgroupbio.com/what-we-do/ -collections

MT Group identifies, collects, and delivers fresh, frozen, and FFPE tissue and other biologics for customized biospecimen collections.

09/22/2025

Why do some biospecimen studies succeed while others fail? It often comes down to operational excellence and attention to detail. Check out our new blog post exploring the critical factors that drive successful biospecimen collection—from strategic planning to quality assurance.

This link will take you to a page that’s not on LinkedIn

09/11/2025

Your brilliant assay won't work if the pre-analytics are wrong.

Liquid biopsy developers can spend years perfecting assays under controlled conditions. Then they deploy clinically and discover performance doesn't match what they found in their lab experiments. The culprit: pre-analytical variables that matter more than they realized.

Critical factors the MT Group helps evaluate in bridging studies for its customer-partners:
* Collection timing: Blood draw to processing timelines (immediate vs. 24+ hours)
* Shipping conditions: Room temperature vs. refrigerated vs. frozen
* Processing variables: Centrifuge speeds, spin times, and equipment types
* Storage protocols: Temperature fluctuations during transit and storage
* Tube selection: Anticoagulants that can affect biomarker stability

The reality: Clinical deployment sites - whether hospitals, central labs, or oncologist offices - vary in their workflows and capabilities. Assays need to be robust to tolerate these variable conditions.

At MT Group, we've conducted A vs. B collections to investigate all of these critical factors. We design bridging studies that compare pre-analytical conditions side-by-side to reveal which variables actually impact assay performance.

Question for the community: Which pre-analytical variable has surprised you most in clinical deployment?

Read more about our take on pre-analytics in our latest blog post. https://lnkd.in/gp64eguZ